Chemomab TherapeuticsCMMB
13F holders, Q3 2025 (September 30)10holders
$2.63avg. 13F price*
At the end of Q3 2025, 10 institutions reported holding Chemomab Therapeutics Ltd. (CMMB) in their 13F filings. The largest holders were Sphera Funds Management LTD. ($472K), Morgan Stanley ($237K) and Ikarian Capital, LLC ($140K).
- Company
- Chemomab Therapeutics Ltd.
- CUSIP
- 16385C203
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $79K |
| Exits | 0 | $0 |
Ownership 10 holders
| Sphera Funds Management LTD. | 0.11% | No change | 179,425 | $472K |
| Morgan Stanley | 0.00% | Reduce -77.0% | 90,065 | $237K |
| Ikarian Capital, LLC | 0.03% | Add +2.8% | 53,262 | $140K |
| Stonepine Capital Management, LLC | 0.06% | New | 30,000 | $79K |
| Jane Street Group, LLC | 0.00% | Add +330.2% | 21,511 | $57K |
| Rhumbline Advisers | 0.00% | Reduce -1.9% | 9,505 | $25K |
| BNP Paribas Financial Markets | 0.00% | Add +70.2% | 5,750 | $15K |
| GAMMA Investing LLC | 0.00% | Reduce -78.6% | 667 | $2K |
| UBS Group AG | 0.00% | Add +2.6% | 99 | $260 |
| SBI Securities Co., Ltd. | 0.00% | Reduce -3.6% | 26 | $68 |
"% of holder's portfolio" is CMMB's weight in each manager's 13F, not the share of Chemomab Therapeutics Ltd. the manager owns.